Compare BBIO & FE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBIO | FE |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 23.9B |
| IPO Year | 2019 | N/A |
| Metric | BBIO | FE |
|---|---|---|
| Price | $77.02 | $44.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 14 |
| Target Price | ★ $77.55 | $48.33 |
| AVG Volume (30 Days) | 1.8M | ★ 4.3M |
| Earning Date | 02-19-2026 | 10-22-2025 |
| Dividend Yield | N/A | ★ 3.96% |
| EPS Growth | N/A | ★ 48.81 |
| EPS | N/A | ★ 2.31 |
| Revenue | $353,780,000.00 | ★ $14,283,000,000.00 |
| Revenue This Year | $127.64 | $10.54 |
| Revenue Next Year | $78.38 | $3.60 |
| P/E Ratio | ★ N/A | $19.49 |
| Revenue Growth | ★ 62.46 | 7.74 |
| 52 Week Low | $27.23 | $37.58 |
| 52 Week High | $78.44 | $48.20 |
| Indicator | BBIO | FE |
|---|---|---|
| Relative Strength Index (RSI) | 64.82 | 46.42 |
| Support Level | $74.47 | $44.80 |
| Resistance Level | $77.48 | $45.20 |
| Average True Range (ATR) | 2.04 | 0.46 |
| MACD | -0.33 | 0.10 |
| Stochastic Oscillator | 73.34 | 72.73 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.